Oct 17 2024 10 mins
In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.
Read the full coverage here:
FDA approves Rybrevant for advanced lung cancer
Lung cancer screening orders in eligible patients higher with digital health program
FDA approves Opdivo regimen for resectable NSCLC
Study quantifies survival benefit of immunotherapy in metastatic NSCLC
FDA expands osimertinib approval for advanced non-small cell lung cancer
References: